Cancer Immunology, Immunotherapy

, Volume 53, Issue 9, pp 786–792

Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer

  • Haruko Yamaji
  • Toshihiko Iizasa
  • Eitetsu Koh
  • Makoto Suzuki
  • Mizuto Otsuji
  • Hao Chang
  • Shinichiro Motohashi
  • Sana Yokoi
  • Kenzo Hiroshima
  • Masatoshi Tagawa
  • Toshinori Nakayama
  • Takehiko Fujisawa
Original Article
  • 259 Downloads

Abstract

Interleukin 6 (IL-6) facilitates the differentiation of B cells to immunoglobulin-secreting cells and is reported to be a proliferative factor in some tumors. In this study, we examined IL-6 production in non-small cell lung carcinoma (NSCLC) and the proliferation of tumor cells following IL-6 treatment in vitro and in vivo. We analyzed the expression of IL-6 mRNA and protein in a series of 15 human lung cancer cell lines (four adenocarcinomas, five squamous cell carcinomas, two large cell carcinomas, and four small cell carcinomas) by reverse transcriptase polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). We established an IL-6-producing cell line (ABC-1#IL-6) by transfecting a human IL-6 cDNA into a human non-IL-6-producing NSCLC cell line (ABC-1). These two cell lines were used to determine tumor cell proliferation both in vivo and in vitro in order to clarify the effect of IL-6 on tumor growth and metastasis. Athymic nude mice, SCID mice, and BALB/c mice were subcutaneously inoculated with these two cell lines, and body weight, tumor growth, and tumor doubling time were measured. The presence of IL-6 and tumor-infiltrating lymphocytes (TILs) within tumor tissues was examined by immunohistochemical staining. Results: Eight of 15 (53%) lung cancer cell lines expressed both IL-6 mRNA and protein. Tumor lesions of both cell lines developed in nude and SCID mice, although no such lesions of either cell lines developed in BALB/c mice. The tumor doubling time in nude and SCID mice was 2.97±1.22 days and 2.45±1.32 days, respectively, in mice inoculated with the cell line ABC-1#IL-6. These doubling times were statistically significantly shorter than those evident in mice inoculated with the control original ABC-1 cell line (nude, p=0.0337; SCID, p=0.0119; unpaired t-test). The rates of cell proliferation in vitro of the ABC-1#IL-6 and original ABC-1 cells lines were comparable (p=0.1441, unpaired t-test). Immunohistochemical staining revealed strong IL-6 expression in tumors derived from the IL-6-producing cell line but not in tumors derived from the original ABC-1 cell line (both in nude and SCID mice). Conclusion: 53% of lung cancer cell lines produce IL-6 mRNA and protein. Although IL-6 itself does not influence tumor cell proliferation in vitro, an association between IL-6 expression and tumor proliferation was found in vivo in nude and SCID mice. An anti-IL-6 reagent could provide a novel therapeutic strategy in patients with IL-6-producing lung tumors.

Keywords

Cytokines Interleukin 6 (IL-6) In vitro In vivo Non-small cell lung cancer (NSCLC) Tumor proliferation 

References

  1. 1.
    Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, Chouaib S, Mami-Chouaib F (1998) Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 77:7–12CrossRefPubMedGoogle Scholar
  2. 2.
    Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, Vignaud J-M (2002) Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host- defence and tumor progression. J Lab Clin Med 140:320–328CrossRefPubMedGoogle Scholar
  3. 3.
    Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP (2000) Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma. Cancer Immunol Immunother 48:627–634CrossRefPubMedGoogle Scholar
  4. 4.
    Huang M, Wang J, Lee P, Sharma S, Mao Jenny T, Meissner H, Uyemura K, Modlin R, Wollman J, Dubinett SM (1995) Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55:3847–3853PubMedGoogle Scholar
  5. 5.
    Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383:787–793PubMedGoogle Scholar
  6. 6.
    Kuninaka S, Yano T, Yokoyama H, Fukuyama Y, Terazaki Y, Uehara T, Kanematsu T, Asoh H, Ichinose Y (2000) Direct influences of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) on the proliferation and cell-surface anigen expression of cancer cells. Cytokine 12:8–11PubMedGoogle Scholar
  7. 7.
    Iizasa T, Fujisawa T, Suzuki M, Shin-ichirou M, Yasufuku K, Yasukawa T, Baba M, Shiba M (1999) Elevated levels of circulating plasma Matrix Metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 149:149–153Google Scholar
  8. 8.
    Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expresion. Biotechniques 7:980–990PubMedGoogle Scholar
  9. 9.
    Mosmann TR, Moore KW (1991) The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 12:49–53Google Scholar
  10. 10.
    Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP (2002) Modulation of tumor-Infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer 36:17–25CrossRefPubMedGoogle Scholar
  11. 11.
    Dosquet C, Schaetz A, Faucher C, Lepage E, Wautier JL, Richard F, Cabane J (1994) Tumour necrosis factor-alpha, interleukin-1beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 30(A):162–167CrossRefGoogle Scholar
  12. 12.
    Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) function as an autocrine growth factor in cevical carcinomas in vitro. Gynecol Oncol 50:15–19CrossRefPubMedGoogle Scholar
  13. 13.
    Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85PubMedGoogle Scholar
  14. 14.
    Mouawad R, Benhammouda A, Rixe O, Antonie E C, Borel C, Weil M, Khayat D, Soubrane C (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 2:1405–1409PubMedGoogle Scholar
  15. 15.
    Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T (1989) Interleukin-6 (IL-6) function as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607–610CrossRefPubMedGoogle Scholar
  16. 16.
    Watson JM, Sensintaffer JL, Berek JS, Martinez-Maza O (1990) Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50:6959–6965Google Scholar
  17. 17.
    Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast Robert C Jr (1992) Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor. Am J Obstet Gynecol 166:997–1007PubMedGoogle Scholar
  18. 18.
    Takizawa H, Ohtoshi T, Ohta K, Yamashita N, Hirohata S, Hirai K, Hiramatsu K, Ito K (1993) Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 53:4175–4181PubMedGoogle Scholar
  19. 19.
    Kishimoto T (1989) The biology of Interleukin-6. Blood 74:1–10PubMedGoogle Scholar
  20. 20.
    Saito K, Ishikura H, Kishimoto T, Kawarada Y, Yano T, Takahashi T, Hiroyuki K, Yoshiki T (1998) Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responces against tumor cells: a possible event in tumor regression. Int J Cancer 75:284–289CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Haruko Yamaji
    • 1
  • Toshihiko Iizasa
    • 1
  • Eitetsu Koh
    • 1
  • Makoto Suzuki
    • 1
  • Mizuto Otsuji
    • 1
  • Hao Chang
    • 1
  • Shinichiro Motohashi
    • 1
  • Sana Yokoi
    • 1
  • Kenzo Hiroshima
    • 2
  • Masatoshi Tagawa
    • 3
  • Toshinori Nakayama
    • 4
  • Takehiko Fujisawa
    • 1
  1. 1.Department of Thoracic Surgery, Graduate School of MedicineChiba UniversityChibaJapan
  2. 2.Department of Clinical PathologyChiba UniversityChibaJapan
  3. 3.Division of PathologyChiba Cancer Center Research InstituteChibaJapan
  4. 4.Department of Medical ImmunologyChiba UniversityChibaJapan

Personalised recommendations